| Myasthenia gravis: recommendations for clinical research standards Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis ... Neurology 55 (1), 16-23, 2000 | 1567 | 2000 |
| 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups IE Lundberg, A Tjärnlund, M Bottai, VP Werth, C Pilkington, M De Visser, ... Arthritis & rheumatology 69 (12), 2271-2282, 2017 | 1363 | 2017 |
| Mutations in Kir2. 1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome NM Plaster, R Tawil, M Tristani-Firouzi, S Canún, S Bendahhou, ... Cell 105 (4), 511-519, 2001 | 1187 | 2001 |
| Randomized trial of thymectomy in myasthenia gravis GI Wolfe, HJ Kaminski, IB Aban, G Minisman, HC Kuo, A Marx, P Ströbel, ... New England Journal of Medicine 375 (6), 511-522, 2016 | 906 | 2016 |
| Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial PH Gordon, DH Moore, RG Miller, JM Florence, JL Verheijde, C Doorish, ... The Lancet Neurology 6 (12), 1045-1053, 2007 | 759 | 2007 |
| Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review)[RETIRED] Report of the Quality Standards Subcommittee of the American Academy of … GS Gronseth, RJ Barohn Neurology 55 (1), 7-15, 2000 | 741 | 2000 |
| Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria RJ Barohn, JT Kissel, JR Warmolts, JR Mendell Archives of neurology 46 (8), 878-884, 1989 | 735 | 1989 |
| Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo‐phase trial CV Oddis, AM Reed, R Aggarwal, LG Rider, DP Ascherman, ... Arthritis & Rheumatism 65 (2), 314-324, 2013 | 698 | 2013 |
| Interferon‐α/β–mediated innate immune mechanisms in dermatomyositis SA Greenberg, JL Pinkus, GS Pinkus, T Burleson, D Sanoudou, R Tawil, ... Annals of Neurology: Official Journal of the American Neurological …, 2005 | 635 | 2005 |
| A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy KR Wagner, JL Fleckenstein, AA Amato, RJ Barohn, K Bushby, ... Annals of neurology 63 (5), 561-571, 2008 | 614 | 2008 |
| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 594 | 2017 |
| Myasthenia gravis: recommendations for clinical research standards1 A Jaretzki, RJ Barohn, RM Ernstoff, HJ Kaminski, JC Keesey, AS Penn, ... The Annals of thoracic surgery 70 (1), 327-334, 2000 | 592 | 2000 |
| Genome-wide analyses identify KIF5A as a novel ALS gene A Nicolas, KP Kenna, AE Renton, N Ticozzi, F Faghri, R Chia, ... Neuron 97 (6), 1267-1288, 2018 | 591 | 2018 |
| Clinical spectrum of chronic acquired demyelinating polyneuropathies DS Saperstein, JS Katz, AA Amato, RJ Barohn Muscle & Nerve: Official Journal of the American Association of …, 2001 | 528 | 2001 |
| Ataluren treatment of patients with nonsense mutation dystrophinopathy K Bushby, R Finkel, B Wong, R Barohn, C Campbell, GP Comi, ... Muscle & nerve 50 (4), 477-487, 2014 | 505 | 2014 |
| Guillain-Barré syndrome and variants MM Dimachkie, RJ Barohn Neurologic clinics 31 (2), 491-510, 2013 | 497 | 2013 |
| Practice parameter: immunotherapy for Guillain–Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology RAC Hughes, EFM Wijdicks, R Barohn, E Benson, DR Cornblath, ... Neurology 61 (6), 736-740, 2003 | 491 | 2003 |
| Myasthenia gravis activities of daily living profile GI Wolfe, L Herbelin, SP Nations, B Foster, WW Bryan, RJ Barohn Neurology 52 (7), 1487-1487, 1999 | 456 | 1999 |
| Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial CM McDonald, C Campbell, RE Torricelli, RS Finkel, KM Flanigan, ... The Lancet 390 (10101), 1489-1498, 2017 | 450 | 2017 |
| A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis RG Miller, JH Petajan, WW Bryan, C Armon, RJ Barohn, JC Goodpasture, ... Annals of neurology 39 (2), 256-260, 1996 | 423 | 1996 |
Mazen DimachkieKUMC在 kumc.edu 的电子邮件经过验证
